Company news
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) news
Rocket Pharmaceuticals, Inc. news releases on 6ix. Latest, Dec 12, 2023: Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors
Press releases — page 2
Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors
December 11, 2023
Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
November 5, 2023
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
October 18, 2023
Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
October 1, 2023
Rocket Pharmaceuticals to Participate in the Chardan 7th Annual Genetic Medicines Conference
September 25, 2023
Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock
September 12, 2023
Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease
September 11, 2023
Rocket Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Progress
August 9, 2023
Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
June 7, 2023
Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease
May 30, 2023
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency (PKD)
May 22, 2023
Rocket Pharmaceuticals Presents Positive Data from LV Hematology and AAV Cardiovascular Gene Therapy Programs at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
May 18, 2023
Rocket Pharmaceuticals Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
May 8, 2023
Rocket Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Progress
May 3, 2023
Rocket Pharmaceuticals to Participate in the Bank of America Securities 2023 Healthcare Conference
May 2, 2023
Rocket Pharmaceuticals Announces Leadership Expansion to Support Company on Evolution Towards Commercial Stage
April 3, 2023
Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference
February 28, 2023
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results
February 26, 2023
Rocket Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
February 8, 2023
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease
February 6, 2023
Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease
January 8, 2023
Rocket Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
January 2, 2023
Rocket Pharmaceuticals Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-of-Phase 1 FDA Meeting
December 21, 2022
Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Pyruvate Kinase Deficiency and Severe Leukocyte Adhesion Deficiency-I Programs at the 64th American Society of Hematology (ASH) Annual Meeting
December 11, 2022
Rocket Pharmaceuticals Completes Acquisition of Renovacor
November 30, 2022
Rocket Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
November 20, 2022
Rocket Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
November 2, 2022
Rocket Pharmaceuticals Announces Presentations Highlighting AAV and Lentiviral Gene Therapies at Upcoming Scientific Congresses
November 2, 2022
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
October 11, 2022
Rocket Pharmaceuticals to Present at the 2022 Cell & Gene Meeting on the Mesa
October 9, 2022
Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock
October 2, 2022
Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
September 29, 2022
Rocket Pharmaceuticals to Present at Chardan 6th Annual Genetic Medicines Conference
September 26, 2022
Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy
September 19, 2022
Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
September 15, 2022
Rocket Pharmaceuticals to Present at Morgan Stanley 20th Annual Global Healthcare Conference
September 5, 2022
Rocket Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
August 7, 2022
Rocket Pharmaceuticals Appoints Mayo Pujols as Chief Technical Officer and Strengthens Manufacturing Capabilities
July 26, 2022
Rocket Pharmaceuticals to Present at William Blair Biotech Focus Conference
July 7, 2022
Rocket Pharmaceuticals Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
May 18, 2022
Rocket Pharmaceuticals Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
May 15, 2022
Rocket Pharmaceuticals to Present at UBS Global Healthcare Conference
May 10, 2022
Rocket Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Progress
May 4, 2022
Rocket Pharmaceuticals to Present at the Bank of America Securities 2022 Global Healthcare Conference
April 26, 2022
Rocket Pharmaceuticals to Present at Upcoming Investor Conferences
March 28, 2022
Rocket Pharmaceuticals Appoints Fady Malik, M.D., Ph.D., to Board of Directors
March 13, 2022
Rocket Pharmaceuticals Appoints Jessie Yeung as Vice President of Investor Relations and Corporate Finance
March 7, 2022
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial and Operational Results
February 23, 2022
Rocket Pharmaceuticals Announces Participation in 11th Annual SVB Leerink Global Healthcare Conference
February 9, 2022
Rocket Pharmaceuticals Highlights Anticipated 2022 Milestones Across Lentiviral and AAV Gene Therapy Clinical Programs
January 10, 2022